Copyright@ Abhinav Kanwal, Shailendra Pratap Singh | Biomed J Sci & Tech Res | BJSTR. MS.ID.004944. 23352 Review Article ISSN: 2574 -1241 Clinical Application of the Main Viral Proteinase (Mpro or 3clpro) Inhibitors for Coronavirus Therapy Abhinav Kanwal 1 * and Shailendra Pratap Singh 2 * 1 Department of Pharmacology, All India Institute of Medical Sciences, Bathinda, Punjab 151001, India 2 Department of Biomedical Engineering, School of Engineering and Technology, Central University of Rajasthan, India *Corresponding author: Shailendra Pratap Singh, Assistant Professor, Department of Biomedical Engineering, School of Engineering and Technology, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer, Rajasthan, 305817, India Abhinav Kanwal, Assistant Professor, Department of Pharmacology, All India Institute of Medical Sciences Bathinda, Punjab 151001, India DOI: 10.26717/BJSTR.2020.30.004944 ARTICLE INFO ABSTRACT The whole world is running behind the coronavirus and coronavirus running around the globe. In this situation, it is a matter of time to develop new immediate medicine to cure these pandemics, as we are aware that vaccines will take lots of time to come into functioning. In this situation, we need to have a drug that can inhibit the spreading of this virus and treat the patient in different ways. Clinical trials are currently investigating the use of various compounds and targets to treat SARS-CoV-2 infection. There are no clinically approved antiviral drugs, vaccines, or monoclonal antibody therapies to treat SARS-CoV infections. Moreover, the continued development of therapeutic and prophylactic countermeasures to potentially deadly coronaviruses is warranted. The coronaviral proteases, specially 3C-like protease (Mpro or 3CLpro), are attractive antiviral drug targets because they are essential for coronaviral replication. Although the Mpro or 3CLpro inhibitor compounds are to process the viral polyprotein. Therefore, targeting Mpro or 3CLpro with inhibitors may have an advantage in not only inhibiting viral replication but also inhibiting the dysregulation of signaling cascades in infected cells that may lead to cell death in the surrounding, uninfected cells. The inhibition of SARS-CoV Mpro or 3CLpro inhibitor compounds, and the prospect of inhibiting papain- like protease from other coronaviruses. Mpro or 3CLpro inhibitor compounds opens the door in the quick treatment of Antiviral therapy against this highly pathogenic human coronavirus.” Received: September 01, 2020 Published: September 15, 2020 Citation: Abhinav Kanwal, Shailendra Pratap Singh. Clinical Application of the Main Viral Proteinase (Mpro or 3clpro) Inhibitors for Coronavirus Therapy. Bi- omed J Sci & Tech Res 30(3)-2020. BJSTR. MS.ID.004944. Introduction The world is suffering from a pandemic of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was ruined in Wuhan (China) and consequently spread worldwide. Several members of the family Coronaviridae continuously circulate in the human population and frequently produce mild respiratory disease [1]. SARS-CoV and another Middle East respiratory syndrome coronavirus (MERS-CoV) are transmitted from animals to humans and instigate severe respiratory diseases in afflicted individuals, SARS, and MERS, respectively [2]. SARS-COV emerged in 2002 in Guangdong province, China, and its subsequent global spread will be associated with 8,096 cases and 774 deaths [2-5]. The Chinese horseshoe bats serve as natural reservoir hosts for SARS-CoV [6,7]. Infection in a human will be transmitted by different intermediate carriers, i.e., raccoon dogs, civet cats, and other animals, which are frequently sold as food sources in Chinese wet markets [6]. There is no specific medicine, drug, vaccine, or therapy to stop the spread and treat the SARS. Furthermore, and the SARS pandemic in 2002 and 2003 will be finally ended by